Arndt Vogel - Nanotechnology

Author Information

A. Vogel is affiliated with the Department of Gastroenterology, Hepatology & Endocrinology at Hannover Medical School in Germany. He is a prominent figure in the field, contributing significantly to the study of liver diseases, particularly hepatocellular carcinoma and liver fibrosis.

Research Contributions

Dr. Arndt Vogel has made substantial contributions to the field of gastroenterology and hepatology. His recent works primarily focus on advanced hepatocellular carcinoma, liver fibrosis, and the use of innovative therapeutic approaches such as mRNA therapeutics and combined drug therapies. His studies often examine the efficacy and safety of various treatments, providing valuable insights into real-world applications and preclinical models. Notably, he has explored the therapeutic potential of HNF4A mRNA in attenuating liver fibrosis and the effects of combined treatments like pembrolizumab, lenvatinib, and bevacizumab on advanced solid tumors.

Aliases

A. Vogel is also known by the aliases "A Vogel" and "Arndt Vogel".

Publication and Citation Metrics

Metric	Value
Total Citations	17,013
h-index	61
Total Papers	478

Publications:

Corrigendum to 'Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model' [J Hepatol (2021) 1420-1433].

DOI: 10.1016/j.jhep.2022.03.023

Year: 2022

Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.

DOI: 10.1200/jco.2022.40.4_suppl.tps669

Year: 2022

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study.

DOI: 10.1002/hep.32468

Year: 2022

Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis.

DOI: 10.1200/jco.2022.40.4_suppl.393

Year: 2022

Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy – a real-world experience

DOI: 10.1055/s-0041-1740781

Year: 2022

Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment

DOI: 10.1007/s00270-021-03031-9

Year: 2022

mRNA therapeutics for liver diseases: HNF4A mRNA delivery via lipid nanoparticles attenuates liver fibrosis in preclinical models.

DOI: 10.1055/s-0041-1740682

Year: 2022

Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase 2 KEYNOTE-224 trial.

DOI: 10.1158/1078-0432.CCR-21-3807

Year: 2022

Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

DOI: 10.1016/j.ejca.2022.02.009

Year: 2022

Variants APOE (rs429358) and TM6SF2 (rs187429064) modify the risk of hepatocellular carcinoma

DOI: 10.1055/s-0041-1740755

Year: 2022

How Does Smart Dust Work?

What are Resonant Cantilevers?

What is Signal Attenuation?

What are the Applications of Micro Molding in Nanotechnology?

What are the Main Objectives of NINT?

Are There Any Risks Associated with the Use of Nanotechnology in Nuclear Applications?

What are some common applications of nanotechnology in research?

What are the Common Scalable Manufacturing Techniques?

What are Digital Control Systems in Nanotechnology?

What are the Ethical Concerns Related to Surveillance and Privacy?

Partnered Content Networks

Relevant Topics